Holtec suspended its planned $900 million IPO the day before expected pricing as nuclear stocks weakened sharply during its roadshow. X-energy fell roughly 24% from September 8 to September 16, worsening the valuation backdrop around Holtec’s proposed $15–$18 offer range.
Holtec cited market conditions, while founder and CEO Kris Singh said the company retained its IPO registration, leaving the HNUC listing delayed rather than abandoned.
Nuclear valuations were already weakening. Standard Nuclear closed 20.6% below its $15 IPO price on September 16.
Holtec was pricing in substantial future growth. EBC’s calculation puts the $15–$18 range at roughly 37.5–45 times Holtec’s 2025 pro forma Class A EPS of $0.40.
The expansion plan is capital intensive. Holtec spent $983.6 million on capital expenditure in 2025 and another $718.4 million in H1 2026.
The IPO could return within three to six months. Nuclear-sector valuations, Palisades progress and acceptable offer pricing will shape any relaunch.
Holtec cited market conditions for suspending the offering, while Singh later linked the decision partly to weaker economic conditions and deteriorating sentiment around AI and data-centre investment themes.
Holtec has not publicly disclosed the strength of its IPO order book, whether prospective buyers pushed back on the proposed price range, or what valuation might have cleared the market. With Holtec disclosing little about investor demand, the clearest evidence of worsening conditions came from the sharp decline in listed nuclear stocks during the roadshow.
The weakness surrounding Holtec was broader than a single listed name. Between September 8 and September 16, X-energy fell 23.9%, NuScale Power lost 25.8%, and Oklo declined 17.8%. Standard Nuclear fell 9.8% over the same period and ended September 16 about 20.6% below its $15 IPO price.
| Nuclear stock | Sept. 8 close | Sept. 16 close |
|---|---|---|
| X-energy | $19.15 | $14.57, -23.9% |
| NuScale Power | $11.18 | $8.30, -25.8% |
| Oklo | $43.31 | $35.62, -17.8% |
| Standard Nuclear | $13.21 | $11.91, -9.8% |
By the end of the roadshow, Holtec was trying to price its IPO against a market backdrop in which listed nuclear names had fallen roughly 10% to 26% in just over a week. The companies are not direct Holtec comparables, but the shared decline showed how quickly public-market appetite for nuclear growth had weakened.
That put more pressure on Holtec’s original $15–$18 range.
Using Holtec’s 2025 pro forma Class A EPS of $0.40, the proposed $15–$18 range equated to roughly 37.5 to 45 times earnings on that per-share measure. The multiple is an EBC calculation based on figures in Holtec’s September prospectus.
The company is also funding a capital-heavy expansion. Holtec spent $983.6 million on capital expenditure in 2025 and another $718.4 million in the first half of 2026, with Palisades accounting for $868.6 million and $639.4 million of those respective totals. Holtec describes the Palisades restart and manufacturing expansion as capital intensive and requiring significant upfront investment before corresponding cash flows arrive.
Holtec reported about $10.57 billion in Nuclear Power Division backlog as of June 30, representing expected future revenue from signed customer contracts. Its roughly 47 GW SMR opportunity pipeline carries greater uncertainty because Holtec has not entered binding agreements to build those reactors or agreed on delivery timelines.
As nuclear stocks repriced lower, that longer-dated growth became harder to value at the original IPO range.
Holtec’s exposure to the AI trade runs through electricity demand. Data-centre expansion has supported expectations for stronger future power consumption, strengthening the commercial case for new nuclear capacity. Holtec’s own prospectus identifies AI, high-performance computing and data-centre growth among the forces lifting electricity-demand expectations.
Singh linked the IPO decision partly to deteriorating sentiment around AI and data-centre investment. Weaker confidence in that spending cycle reduces some of the premium attached to long-term nuclear growth, particularly projects such as SMR-300 that still depend on financing, customer commitments and commercial deployment.
Holtec’s established nuclear-services operations are less exposed to that shift. The pressure falls more heavily on the future-growth portion of the valuation that public markets were being asked to price into the IPO.
Holtec has postponed the IPO rather than abandoned it, and Singh said the company could return within three to six months. No new pricing date has been announced.
Three variables will shape any relaunch: nuclear-sector valuations, execution progress at Palisades and commercial traction behind Holtec’s future reactor pipeline.
Offer pricing will remain the final market test. Better operating progress can support a stronger valuation case, while weak public nuclear valuations would continue to limit how much of Holtec’s future growth the market is prepared to price in.
Holtec does not need the same market it had in September. It needs a stronger case at the price the market is prepared to clear.
